Sugi Predict

Sugi Predict / Compounds / SCHEMBL18988959

SCHEMBL18988959

SCHEMBL18988959

CC(C)(C)C(N(N)C(=O)c1ccccc1)C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MLYCD O95822 2/20 0.42
▸ POLB P06746 1/20 0.41
▸ NR1H3 Q13133 2/20 0.39
▸ NR1H2 P55055 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ TRPM8 Q7Z2W7 3/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ RECQL P46063 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HSD11B1 P28845 1/20 0.36
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28658327 0.81 MLYCD (0.46) MLYCDPOLBNR1H3NR1H2CES1
SCHEMBL18988683 0.80 MLYCD (0.48) MLYCDPOLBNR1H3NR1H2CES1
SCHEMBL23150369 0.77 TRPM8 (0.43) MLYCDPOLBNR1H3NR1H2CES1
SCHEMBL28964406 0.75 MLYCD (0.50) MLYCDPOLBNR1H3NR1H2CES1
SCHEMBL18988787 0.75 TRPM8 (0.41) MLYCDPOLBNR1H3NR1H2CES1
SCHEMBL28320439 0.74 TRPM8 (0.45) MLYCDPOLBCES1TRPM8ALDH1A1
SCHEMBL31388076 0.73 ADRA2C (0.43) MLYCDPOLBCES1TRPM8ALDH1A1
SCHEMBL4667859 0.73 TRPM8 (0.47) MLYCDPOLBCES1TRPM8ALDH1A1
SCHEMBL18989293 0.72 MLYCD (0.38) MLYCDNR1H3NR1H2CES1TRPM8
SCHEMBL27797561 0.72 PRSS1 (0.41) POLBCES1TRPM8ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250090500-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2025-03-20 — — US disclosed
US-12220401-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY, INC. (US) 2025-02-11 — — US disclosed
US-11826351-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY INC. (US) 2023-11-28 — — US disclosed
US-20230372298-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2023-11-23 — — US disclosed
CN-114716381-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-07-08 — — CN disclosed
CN-114634447-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-17 — — CN disclosed
CN-114621146-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-14 — — CN disclosed
CN-114605327-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-10 — — CN disclosed
CN-114591242-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-07 — — CN disclosed
CN-114573510-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-03 — — CN disclosed
US-20210093611-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2021-04-01 — — US disclosed
US-10918622-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY, INC. (US) 2021-02-16 — — US disclosed
US-20200276162-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2020-09-03 — — US disclosed
US-10464905-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY INC. (US) 2019-11-05 — — US disclosed
US-10342780-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY, INC. (US) 2019-07-09 — — US disclosed
US-20190000806-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2019-01-03 — — US disclosed
US-20180362512-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2018-12-20 — — US disclosed
EP-3390395-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS Loxo Oncology Inc. (US) 2018-10-24 — — EP disclosed
CN-108473481-A compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2018-08-31 — — CN disclosed
WO-2017103611-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS REDX PHARMA PLC (GB) 2017-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12220401-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK MLYCD 3067/4885POLB 2773/4885NR1H3 4145/4885
US-20250090500-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK MLYCD 3067/4885POLB 2773/4885NR1H3 4145/4885
US-20180362512-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK MLYCD 3067/4885POLB 2773/4885NR1H3 4145/4885
US-10918622-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK MLYCD 3067/4885POLB 2773/4885NR1H3 4145/4885
US-20200276162-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK MLYCD 3067/4885POLB 2773/4885NR1H3 4145/4885
US-11826351-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK MLYCD 3067/4885POLB 2773/4885NR1H3 4145/4885
US-20230372298-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK MLYCD 3067/4885POLB 2773/4885NR1H3 4145/4885
US-20210093611-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK MLYCD 3067/4885POLB 2773/4885NR1H3 4145/4885
US-10464905-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK MLYCD 3067/4885POLB 2773/4885NR1H3 4145/4885
US-10342780-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK MLYCD 3067/4885POLB 2773/4885NR1H3 4145/4885
US-20190000806-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK MLYCD 3067/4885POLB 2773/4885NR1H3 4145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback